Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of…
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers. The post Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type…
Neko Health Secures $700M to Support US Expansion
Neko’s Series C round was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD. The post Neko Health Secures $700M to Support US Expansion appeared first on MedCity News.
A Profile of Dual-Eligible Individuals
Approximately 12 million people are enrolled in both Medicare and Medicaid, referred to as dual-eligible individuals. This brief examines the demographic, socioeconomic, and health characteristics of dual-eligible individuals compared with Medicare beneficiaries without Medicaid.
Five Key Facts About Spending and Enrollment for People with Medicare and Medicaid (Dual-Eligible Individuals)
This issue brief analyzes provides a profile of enrollment and spending on dual-eligible individuals, drawing on new analysis of data on chronic conditions to show how higher rates of chronic conditions contribute to higher average spending among this population.
Answers at the Speed of Thought: Healthcare Analytics in the Era of Agentic AI
We are moving into an era where we can finally converse with our data. We can ask, “Why are denials spiking in Region X?” or “Show me the safety profile of this cohort,” and receive an answer, not a spreadsheet. The post Answers at the Speed of Thought: Healthcare Analytics in the Era of Agentic…
The Measurement Problem Behind Two Decades of Neurology Trial Failures
The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention. The post The Measurement Problem Behind Two Decades of Neurology Trial Failures appeared first on MedCity News.
Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk
You cannot secure what you cannot see, and right now, healthcare organizations are accumulating hidden cyber liabilities with every keystroke. The post Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk appeared first on MedCity News.
Payers Who Improve Data Quality Will Define the Next Era of Health Plan Performance
[Sponsored] On July 22, a webinar sponsored by Verato will spotlight perspectives of executives from Scan Health Plan and the Alliance of Community Health Plans. The post Payers Who Improve Data Quality Will Define the Next Era of Health Plan Performance appeared first on MedCity News.
Facing Funding Losses, States Call Out Big Businesses With Employees on Medicaid
As the Trump administration’s January deadline looms for states to enforce new Medicaid work requirements, some state lawmakers are turning the tables by pushing to publicly name the largest companies that have employees enrolled in the government program covering low-income and disabled people. California lawmakers seek to revive an expired law that would require the…
Value Is in the Eye of the Beholder
By KIM BELLARD The most (unintentionally) amusing story I read this week was Tim Higgin’s Wall Street Journal article Alex Karp Is Saying What Every Angry CEO Is Thinking About AI. Dr. Karp (yes, he has a Ph.D.), co-founder and CEO of Palantir Technologies, is upset about how AI companies are using relationships with their…
